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Glutaric aciduria (GTA) type II can be seen as late onset form with myopathic phenotype. We present a
case of a 19-year old female with progressive muscle weakness was admitted in intensive care unit (ICU)
with respiratory failure and acute renal failure. Patient was unconscious. Pupils were anisocoric and light
reﬂex was absent. She had hepatomegaly. The laboratory results showed a glucose level of 70 mg/dl and
the liver enzymes were high. The patient also had hyponatremia (117 mEq/L) and lactate level of
3.9 mmol/L. Tandem MS and organic acid analysis were compatible with GTA type II. Carnitine 1gr,
riboﬂavin 100 mg and co-enzymeQ10 100 mg was arranged. After four months from beginning of
treatment tandem MS results are improved.
Respiratory failure, acute renal failure due to profound proximal myopathy can be due to glutaric
aciduria type II that responded rapidly to appropriate therapy.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Glutaric aciduria (GTA) type II is an autosomal recessive disease.
Different substrates like abnormal amino acids and/or fatty acids
metabolites together with high amounts of glutaric acid accumu-
late due to a block in electron transfer between the acyl-CoA de-
hydrogenases and the respiratory chain [1,2].
There are mainly three clinical phenotypes which can be seen in
GTA type II: First, neonatal formwith congenital anomalies. Second,
neonatal form without congenital anomalies. And third late onset
form with myopathic phenotype and rarely metabolic acidosis [1].
We present a case of late onset GTA type II characterized by res-
piratory failure and acute renal failure.
Case
A 19-years old female with progressive muscle weakness and
dyspneawas admitted in intensive care unit (ICU). In admission the
patient was unconscious and intubated. The physical examination
showed anisocoric pupils with a right dilated pupil and the light
reﬂex was absent. Examination was normal except hepatomegaly.
The patient had hyponatremia, hypoglisemia and hyperlactatemia.
The results are shown in Table 1.y).
Ltd. This is an open access article uRadiologic ﬁndings showed cortical changes which were usually
seen due to hypoglycemia (Figs. 1 and 2).
TandemMS and organic acid analysis were compatible with GTA
type II (Table 2).
She was treated with carnitine 1gr, riboﬂavin 100 mg and co-
enzymeQ10 100 mg. In addition to the drug therapy hemodialysis
was performed to get rid of the accumulated metabolites and
glutaric acid. The patient showed progressive recovery andwith the
help of physiotherapy. Ability to swallow and walk was dramati-
cally improved. After four months from beginning of treatment
Tandem MS results are improved (Table 2).Discussion
We describe a rare cause of acute respiratory failure due to
myopathy in a young adult. Differential diagnosis of acute respi-
ratory failure in young adults includes infectious diseases, chronic
respiratory diseases, intoxications, neuromuscular diseases and
metabolic diseases (causing myopathy) [3]. There are many etiol-
ogies of myopathy, including toxicologic, endocrinologic, and
metabolic causes.
Late onset GTA type II [4,5] can be the cause of myopathy,
especially in cases of childhood onset. The mode of presentation of
older patients included a progressive lipid-storage myopathy [6]
muscle weakness and myalgia [7], and repeated episodes of hy-
poglycemia with hypoketosis, accompanied by proximal myopathynder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Laboratory ﬁndings of patient at admission.
Patients results References
ALT (U/L) 412 <33
AST (U/L) 1366.7 <31
GGT (U/L) 464.9 <33
ALP (U/L) 128 <390
Sodium (mEq/L) 117.3 130e140
Potassium (mEq/L) 4.8 3.5e5.1
Chlor (mEq/L) 86.4 95e110
BUN(mg/dL) 57.6 6e20
Creatin(mg/dL) 2.5 0.5e0.9
Uric acide (mg/dL) 10.7 2.4e5.7
Protein,total (g/dL) 4.7 6.4e8.3
Albumin (g/dL) 2.8 3.4e4.8
LDH (U/L) 7604 240e480
CK (U/L) 11511 26e192
Calcium (mg/dL) 7.6 8.6e9.9
Hemoglobine (g/dL) 11.3 11.7e15.5
Hemotocride % 33% 34.5e46.3
WBC (x1000/ml) 14.1 4.1e11.2
PLT (x1000/ml) 198 159e388
lactate (mmol/L) 3.9 0.8e2
Table 2
Tandem MS results; before and after treatment.
Before treatment After treatment
Free carnitine 41.24 mmol/L 53.11
C5 2.88 mmol/L (normal)
C6 0.66 mmol/L (normal)
C5 OH 0.80 mmol/L normal
C8 1.47 mmol/L 1.58
C10 2.67 mmol/L 2.65
C10:1 0.50 mmol/L 0.56
C4DC 1.62 mmol/L 1.68
C5DC 3.04 mmol/L normal
C12 2.08 mmol/L 1.29
C6 1.14 mmol/L normal
Metylglutaryl carnitine 2.06 mmol/L normal
C14:2 0.54 mmol/L normal
C14:1 1.48 mmol/L 0.63
C14 0.39 mmol/L 0.64
C16:1 0.96 mmol/L 0.21
C16 1.70 mmol/L normal
C18:2 0.87 mmol/L 0.70
C18:1 2.36 mmol/L normal
C18 0.99 mmol/L 0.63
Leucin/isoleucin 366 mmol/L normal
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and acidosis may predominate [8,9] as seen in our case muscle
weakness is a common ﬁnding of patients with late onset glutaric
aciduria type II [5]. It predominantly affects proximal muscles and
may lead to hypoventilation.Fig. 1. Brain CT: ﬂattened sulci secondary to the diffuse brain edema.
Fig. 2. Brain MRI: cortical changes which were usually seen due to hypoglycemia.Acylcarnitine analysis with tandem mass spectrometry is a very
useful diagnostic tool for GTA type II. Apart from GTA type II, dis-
orders of riboﬂavin transport can present with similar clinical and
biochemical features. RFT2 (C20orf54) is thought to be primary
intestinal riboﬂavin transporter. RFT2 defects cause Brown-
Vialetto-van Laere syndrome, an autosomal recessive disorder
that presents with hypotonia and respiratory failure in infancy or,
later in life, with deafness and pontobulbar palsy; in the absence of
deafness, it is known as Fazio-Londe disease. Fazio-Londe disease,
also called progressive bulbar palsy of childhood, is an inherited
motor neuron disease found in children and young adults. Blood
acylcarnitines and urine organic acids suggest GTA type II, and
treatment with riboﬂavin leads to clinical and biochemical
improvement.
As in most inborn errors of metabolism, investigation for
electron transfer defects including GTA type II and Fazio-Londe
disease starts with a search for abnormal metabolites, particu-
larly acylcarnitines. If the results suggest a speciﬁc diagnosis, this
is conﬁrmed with by enzyme assays or mutation analysis [10]. In
our patient biochemical and clinical ﬁndings were typical for GTA
type II, however, enzyme or mutation analysis could not be
performed.
Urine organic acid analysis may not be helpful in the stable form
of GTA type II, because levels are often normal except during a
symptomatic period. During acute episodes, the analysis may
demonstrate dicarboxylic acid compounds (suberic acid, sebacic
acid, and adipic acid), as we demonstrated.
Carnitine supplement may be required, given secondary carni-
tine deﬁciency reported in a patient with glutaric aciduria type II
[11]. Carnitine supplement alone may not be sufﬁcient. For better
outcome riboﬂavin and coeenzyme Q 10 can be added [7e9,12].
Riboﬂavin therapy resulted in a dramatic improvement in both
clinical and biochemical aspects. In our patient, the defect in co-
enzyme binding to electron transfer ﬂavoprotein (ETF) or ETF-
dehydrogenase was suspected. However, it was the limitation of
our manuscript that, enzyme or mutation analysis could not be
performed.
We present a rare cause of respiratory failure, acute renal failure
due to profound proximal myopathy that responded rapidly to
appropriate therapy. Since late-onset GTA type II is treatable, cor-
rect diagnosis is of utmost importance and should be considered in
adults.
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